PubRank

Jorma Isola

Author PubWeight™ 142.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 9.85
2 Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007 5.44
3 Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004 4.01
4 Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2007 3.95
5 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002 3.70
6 Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009 3.63
7 ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010 3.54
8 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006 2.89
9 Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol 2005 2.56
10 Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004 2.47
11 Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005 2.39
12 Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003 2.15
13 Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002 2.06
14 HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011 2.01
15 Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005 1.93
16 Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007 1.91
17 Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003 1.87
18 CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009 1.81
19 The application of JPEG2000 in virtual microscopy. J Digit Imaging 2007 1.76
20 A web-based system for individualised survival estimation in breast cancer. BMJ 2003 1.70
21 ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004 1.70
22 Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007 1.70
23 Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003 1.65
24 Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007 1.54
25 Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002 1.54
26 HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002 1.53
27 Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008 1.53
28 Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2005 1.53
29 Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 2002 1.51
30 Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 2006 1.51
31 Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011 1.46
32 Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) 2006 1.43
33 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009 1.43
34 Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 2011 1.42
35 Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging 2009 1.39
36 Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011 1.39
37 Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005 1.38
38 Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006 1.38
39 Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007 1.37
40 Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004 1.37
41 Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010 1.35
42 EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008 1.31
43 ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry. Histopathology 2012 1.30
44 Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res 2003 1.27
45 Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003 1.23
46 Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014 1.21
47 Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol 2012 1.20
48 Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011 1.18
49 Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2007 1.14
50 Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 2003 1.14
51 Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest 2003 1.10
52 Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance. PLoS Negl Trop Dis 2008 1.08
53 Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol 2004 1.08
54 Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol 2011 1.07
55 Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 2005 1.06
56 Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep 2010 1.05
57 Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 2003 1.04
58 Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007 1.04
59 The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol 2008 1.02
60 Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 2010 1.01
61 Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet 2007 0.98
62 Cancer incidence in families with multiple glioma patients. Int J Cancer 2002 0.98
63 Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res 2005 0.97
64 Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 2006 0.96
65 Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogenet 2006 0.92
66 Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives. J Clin Pathol 2013 0.91
67 Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res 2011 0.91
68 Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett 2007 0.90
69 Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol 2009 0.90
70 Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol 2012 0.89
71 Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 2005 0.88
72 Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. Eur J Cancer 2006 0.88
73 Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer 2012 0.87
74 HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res 2009 0.86
75 Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer 2009 0.85
76 A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model. J Gastrointest Surg 2007 0.85
77 Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry. J Urol 2006 0.84
78 A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2009 0.83
79 Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002 0.83
80 Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol 2014 0.83
81 Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol 2009 0.82
82 Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer 2009 0.81
83 Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes Cancer 2012 0.81
84 Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. J Otolaryngol Head Neck Surg 2010 0.80
85 Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod Pathol 2005 0.80
86 Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Scand J Gastroenterol 2006 0.79
87 Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Int J Gynecol Pathol 2014 0.79
88 The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. Int J Clin Exp Pathol 2013 0.78
89 Evaluation of a web-based system for survival estimation in breast cancer. Stud Health Technol Inform 2003 0.78
90 Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein. J Cell Biochem 2011 0.78
91 Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. Int J Oncol 2002 0.78
92 Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. Cancer Genet Cytogenet 2003 0.76
93 Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation. Genes Chromosomes Cancer 2002 0.76
94 Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecol Oncol 2004 0.76
95 Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes Cancer 2015 0.76
96 Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins. PLoS One 2011 0.76
97 L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. Int J Gynecol Cancer 2016 0.75
98 The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. Mol Cancer Ther 2005 0.75
99 Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. Hum Pathol 2011 0.75
100 [Targeted cytotoxic drugs emerging for cancer therapy]. Duodecim 2011 0.75
101 Analyzing toposimerase II-alpha and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer. Acta Oncol 2009 0.75
102 Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult. Scand J Gastroenterol 2009 0.75
103 Ultra thin needle histology may have impact in diagnosing chronic pancreatitis. Scand J Gastroenterol 2007 0.75
104 Validation of a Web-based prognostic system for breast cancer. Stud Health Technol Inform 2004 0.75
105 Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. Appl Immunohistochem Mol Morphol 2016 0.75
106 [Clinical pathology on the verge of virtual microscopy]. Duodecim 2015 0.75